Phase I II Trial

LONDON, United Kingdom, July 23, 2026 GSK plc has announced that the U.S. Food and Drug Administration (FDA) has...

BASEL, Switzerland, June 11, 2026 Novartis has announced positive results from the FORTITUDE Phase I/II clinical study evaluating delpacibart...